Cochlear

What Cochlear does

Cochlear Limited is an Australian-headquartered (ASX:COH) global medical device company that designs, manufactures, and distributes implantable hearing solutions for individuals with severe to profound sensorineural, conductive, and mixed hearing loss and single-sided deafness. Founded in 1981 by Professor Graeme Clark following his 1978 invention of the multi-channel cochlear implant, the company lists more than 750,000 implantable devices delivered worldwide and a presence in more than 50 countries with six global manufacturing sites (four in Asia Pacific) and regional offices spanning the Americas, Europe, Middle East, and Africa. Its product platform centers on three core systems: the Cochlear Nucleus Nexa System (CI1000 internal implant plus Nucleus 8 Nexa and Kanso 3 Nexa sound processors, featuring upgradeable firmware, internal memory, MRI compatibility at 1.5T/3.0T without magnet removal, and machine learning environment adaptation), the Cochlear Osia System (active osseointegrated bone conduction implant for conductive, mixed, and single-sided deafness), and the Cochlear Baha System (bone conduction solution). Supporting software includes Custom Sound Pro (clinician fitting), Cochlear Link (cloud sync), Nucleus SmartNav (surgical navigation), and the Nucleus, Baha, and Osia Smart Apps with bimodal integration to ReSound hearing aids and Made-for-iPhone/Android direct audio streaming.

Cochlear's business model is hardware-led with a recurring service overlay. Primary revenue comes from sales of cochlear implants and bone conduction devices through a clinical channel of ENT surgeons, audiologists, neurotologists, hospitals, and US VA clinics, supplemented by direct-to-consumer engagement via the Cochlear Family membership program, volunteer ambassadors, and the company's online store for accessories and sound processor upgrades. Connected care services (Remote Check, Remote Assist) extend the relationship beyond the surgical episode. The company acquired Oticon Medical from Demant A/S in May 2024, integrating approximately 20,000 users and adding R&D and manufacturing capacity, and in 2026 launched the Nucleus Nexa System in India and at US VA clinics. Financial scale places Cochlear in the multi-billion dollar revenue band (H1 FY2026 revenue of $1,176M, 1% growth; FY2025 ~$1.54B), with FY2026 underlying net profit guided to AUD 435–460M. Risks concentrated in 2026 include a 41% stock decline on guidance cut, 9% H1 profit decline, gross margin compression to 73%, AUD 30M H2 currency headwind, and a $9.2M write-down in its Saluda investment.

Customers fall into overlapping segments: severe-to-profound hearing-loss adults as the primary commercial segment, pediatric patients (including congenital loss), US military veterans, and healthcare professionals as clinical decision-makers. Distribution is hybrid — enterprise field sales for implants via clinic and hospital networks, direct-to-consumer marketing for awareness and post-sale engagement, and regional distributors across the Middle East and Africa. Pricing is not publicly disclosed and is driven by reimbursement frameworks (Medicare/Medicaid, private insurance, national health systems) and regional healthcare economics.

Name

Cochlear

Legal name

Cochlear Limited

Website

https://cochlear.com

Company type

Public

Founded year

1981

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Cochlear Limited is the global leader in implantable hearing solutions, serving individuals with severe to profound, conductive, mixed, and single-sided deafness through its Nucleus Nexa smart cochlear implant, Osia bone conduction, and Baha systems, distributed via ENT surgeons, audiologists, hospitals, and VA clinics across more than 50 countries.

Ownership category

akta.pro rank

Product category

Cochlear Implants / Implantable Hearing Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Otology & Neurotology (Ear/Hearing/Balance) (HLAKAMAC)

akta.pro secondary industry

Audiology & Hearing Services (ENT-Affiliated) (HLAKAMAI)

Keywords

• Cochlear implants
• Bone conduction hearing
• Implantable hearing devices
• Hearing prosthetics
• Sound processors

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices6 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Cochlear Implants: Sale of cochlear implant devices including internal implants and external sound processors. Devices are sold through healthcare providers and clinics. Revenue is generated from initial device sales and subsequent upgrades.
2. Sound Processors and Accessories: Replacement and upgrade sound processors, batteries, and accessories sold to existing implant recipients. Ongoing revenue from device maintenance and upgrades.
3. Bone Conduction Systems (Baha, Osia): Sale of bone conduction hearing implants and associated sound processors for patients with conductive, mixed hearing loss or single-sided deafness.
4. Connected Care Services: Remote care services including Remote Check and Remote Assist for virtual audiology appointments and health monitoring, supporting ongoing patient care.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

Cochlear designs, manufactures, and sells implantable hearing systems for individuals with severe to profound, conductive, mixed, and single-sided hearing loss. Its core product lines comprise the Nucleus cochlear implant platform (including the Nexa smart implant and compatible sound processors), the Osia active osseointegrated bone conduction system, and the Baha bone conduction system. The company also provides connected care digital services (Remote Check, Remote Assist, Cochlear Link), fitting software for clinicians, and recipient support programs (Cochlear Family, volunteer network).

Product overview

Cochlear is a medical technology company specializing in implantable hearing solutions. The product portfolio centers on three core hearing implant systems: the Cochlear Nucleus Nexa System (smart cochlear implant with upgradeable firmware), the Cochlear Osia System (active osseointegrated bone conduction implant for conductive/mixed hearing loss and SSD), and the Cochlear Baha System (bone conduction hearing solution). Each system includes compatible sound processors available in behind-the-ear (Nucleus 8 Nexa) and off-the-ear (Kanso 3 Nexa) form factors. Supporting these core products are connected care services including Remote Check (virtual assessments), Remote Assist (virtual appointments), Cochlear Link (cloud synchronization), and SmartNav (surgical navigation), along with recipient programs such as Cochlear Family and Cochlear Academy for professional training. The Nucleus Smart App, Baha Smart App, and Osia Smart App provide recipient control and streaming via Apple and Android devices, with bimodal integration to ReSound hearing aids.

Differentiator

Problem solved

Functional benefit

Brands

• Nucleus: Cochlear implant system brand including Nexa System, sound processors (Nucleus 8, Kanso 3), and related technology
• Baha
• Osia
• Cochlear Family
• Nucleus Smart App
• Baha Smart App
• Osia Smart App
• Custom Sound
• Cochlear Family Program
• Cochlear Volunteer Program

Products and services

• Cochlear Nucleus Nexa System The Cochlear Nucleus Nexa System is described as the world's first and only smart cochlear implant system with upgradeable firmware and internal memory. It comprises the CI1000 Nexa implant and compatible sound processors (Nucleus 8 Nexa, Kanso 3 Nexa), featuring automatic environment adaptation and remote firmware update capabilities.
• Cochlear Nucleus Implant (CI1000 Nexa) The Cochlear Nucleus Implant is the internal cochlear implant device with 22 active electrode contacts for precise frequency coverage. The CI1000 Nexa variant features internal memory and upgradeable firmware, described as the world's thinnest full-length electrode.
• Nucleus 8 Nexa Sound Processor The Nucleus 8 Nexa Sound Processor is a behind-the-ear sound processor positioned as one of the world's smallest and lightest in its category, designed for Nucleus cochlear implant recipients. It features next-generation Bluetooth LE Audio connectivity, direct smartphone streaming, and SmartSound iQ 2 with SCAN 2 for automatic environment adaptation.
• Kanso 3 Nexa Sound Processor The Kanso 3 Nexa Sound Processor is an off-the-ear sound processor offering freedom, comfort, and discreet design. Described as the world's smallest and lightest rechargeable off-the-ear sound processor with all-day battery life.
• Cochlear Osia System The Cochlear Osia System is an active osseointegrated steady-state implant system providing a bone conduction hearing solution. It addresses conductive hearing loss, mixed hearing loss, and single-sided sensorineural deafness through discreet bone-conduction technology with innovative design.
• Cochlear Baha System The Cochlear Baha System is a bone conduction hearing solution with sound processors providing power for individuals with conductive or mixed hearing loss. Features True Wireless connectivity and smart hearing technology.

Quantifiable outcome

• Nucleus Nexa Implant delivers 100% CSP (Cumulative Survival Percentage) within 2 years based on clinical studies.
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability4 records

Feature7 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Nyxoah SAminorStrategic or Co-development Partner · 10 June 2026Cochlear previously held approximately 15% stake in Nyxoah through its subsidiary Cochlear Investments Pty Ltd. Following Nyxoah's capital increase and private placement in November 2025, Cochlear's stake passively decreased to 5.85%, crossing below the 10% threshold. The collaboration with Nyxoah has effectively concluded according to Nyxoah's June 2026 disclosures.
• Oticon Medical (Demant A/S)coreStrategic or Co-development Partner · 1 May 2024In May 2024, Cochlear acquired Oticon Medical, the cochlear implant division of Denmark's Demant A/S, for an undisclosed sum. This strategic acquisition was intended to expand Cochlear's scale, accelerate research and development, and integrate Oticon Medical's approximately 20,000 users into its technology ecosystem.
• Healthcare Organizations and ClinicscoreChannel Partner/ Reseller/ DistributorCochlear works with healthcare organizations, hospitals, clinics, audiologists, and surgeons globally to provide cochlear implantation services and ongoing patient care.
• SycleminorChannel Partner/ Reseller/ DistributorSycle, a provider of practice management software for hearing care, hired Craig Sharp from Cochlear where he served as VP of Connected Care and Digital Products for eight years. Sycle serves over 8,000 hearing clinics in 13 countries.

Scale indicators12 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• MED-EL: MED-EL is the second-largest global manufacturer of cochlear implants, headquartered in Austria. It directly competes with Cochlear across cochlear implant systems, sound processors, and bone conduction solutions for similar patient populations with severe to profound hearing loss.
• Sonova (Advanced Bionics): Sonova owns Advanced Bionics, a direct competitor in cochlear implants, and is the world's largest hearing aid company through brands Phonak, Unitron, and Hansaton. Overlaps with Cochlear across implantable hearing solutions, bimodal hearing, and connected care ecosystems.

Regional players

• Shenzhen Nurotron Biotechnology: Nurotron is a China-based cochlear implant manufacturer serving primarily the domestic Chinese market. Comparable as a regional player in the same cochlear implant category with overlapping technology and patient population, representing potential competitive pressure in Asia-Pacific.

Broad incumbents

• Demant A/S: Demant is the parent of Oticon (hearing aids) and previously Oticon Medical (now acquired by Cochlear). As a broad incumbent in hearing healthcare with diagnostic instruments, hearing aids, and cochlear implants, it is highly comparable as both a partner history and a benchmark for global hearing industry scale.
• Starkey Hearing Technologies: Starkey is a major US-based hearing aid manufacturer and a technology innovator (e.g., AI-enabled hearing aids). Comparable as a global hearing healthcare incumbent that competes for audiologist relationships and consumer awareness with Cochlear's Nucleus sound processors.
• WS Audiology (Widex, Signia): WS Audiology is a top global hearing aid manufacturer formed from the merger of Widex and Sivantos (Signia). It is comparable as a broad incumbent in hearing healthcare sharing target customers (ENTs, audiologists) and competing for clinician mindshare with Cochlear's sound processor upgrade ecosystem.
• GN Hearing (ReSound): GN Hearing is one of the world's largest hearing aid manufacturers (ReSound, Beltone, Jabra) and a direct partner of Cochlear in bimodal hearing solutions. Comparable as a hearing healthcare leader with overlapping clinician relationships and consumer reach.

Emerging players

• Nyxoah SA: Nyxoah is a Belgium-based medical device company developing the Genio hypoglossal nerve stimulation system for obstructive sleep apnea. Comparable as a small-cap implantable neurostimulation company with which Cochlear previously had a strategic minority stake and partnership (now concluded).
• Envoy Medical: Envoy Medical is an emerging US-based player developing active middle ear implants and fully implanted hearing devices. Comparable as a niche competitor in implantable hearing technology that could disrupt portions of Cochlear's addressable market with novel surgical alternatives.

Others

• LivaNova: LivaNova is a global medical device company with implantable technologies in cardiovascular and neuromodulation (VNS therapy). Comparable as an adjacent implantable medical device peer with similar regulatory pathways, R&D intensity, and clinical evidence requirements, though not directly competing in hearing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CochlearGlobal
• YouTubeyoutube.com/user/CochlearAmericas
• Facebookfacebook.com/cochlear
• LinkedInlinkedin.com/company/cochlear
• Instagraminstagram.com/cochlearamericas

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cochlear